Your browser doesn't support javascript.
loading
High rate of local control and cure at 10 years after treatment of prostate cancer with external beam radiotherapy and high-dose-rate brachytherapy: a single centre experience.
Hjälm-Eriksson, Marie; Nilsson, Sten; Brandberg, Yvonne; Johansson, Hemming; Lennernäs, Bo; Lundell, Göran; Castellanos, Enrique; Ullén, Anders.
Afiliación
  • Hjälm-Eriksson M; Department of Oncology-Pathology, Karolinska Institute, Stockholm, Sweden.
  • Nilsson S; Department of Oncology, Capio S:t Göran's Hospital, Stockholm, Sweden.
  • Brandberg Y; Department of Oncology-Pathology, Karolinska Institute, Stockholm, Sweden.
  • Johansson H; Department of Pelvic Cancer, Genitourinary Oncology and Urology Unit, Karolinska University Hospital, Stockholm, Sweden.
  • Lennernäs B; Department of Oncology-Pathology, Karolinska Institute, Stockholm, Sweden.
  • Lundell G; Department of Pelvic Cancer, Psychosocial Unit, Karolinska University Hospital, Stockholm, Sweden.
  • Castellanos E; Department of Oncology-Pathology, Karolinska Institute, Stockholm, Sweden.
  • Ullén A; Department of Oncology-Pathology, Karolinska Institute, Stockholm, Sweden.
Acta Oncol ; 60(10): 1301-1307, 2021 Oct.
Article en En | MEDLINE | ID: mdl-34498986
ABSTRACT
BACKGROUND AND

PURPOSE:

To analyse the cumulative incidence of any failure (AF), prostate cancer-specific failure (PCSF), any death (AD), prostate cancer-specific death (PCSD), and local control in 2387 men with prostate cancer (PC), consecutively treated with combined high-dose-rate brachytherapy (HDRBT) and external beam radiotherapy (EBRT) from 1998 to 2010. MATERIAL AND

METHODS:

A retrospective, single-institution study of men with localised PC. The mean age was 66 years and 54.7% had high-risk PC according to the Cambridge prognostic group (CPG) classification. The treatment was delivered as EBRT (2 Gy × 25) and HDRBT (10 Gy × 2) with combined androgen blockade (CAB). The median follow-up was 10.2 years.

RESULTS:

The cumulative incidence of PCSD at 10 years was 5% [CI 95% 0.04-0.06]. The 10 years PCSD per risk group were low (L) 0.4%, intermediate favourable (IF) 1%, intermediate unfavourable (IU) 4.3%, high-risk favourable (HF) 5.8%, and high-risk unfavourable (HU) 13.9%. The PCSF rate at 10 years was 16.5% [CI 95% 0.15-0.18]. The PCSF per risk group at 10 years were L 2.5%, IF 5.5%, IU 15.9%, HF 15.6%, and HU 38.99%. PCSF occurred in 399 men, of whom 15% were found to have local failure. The estimated frequency of local failure in the entire cohort was 1.2%.

CONCLUSIONS:

HDRBT combined with EBRT is an effective treatment with long-term overall survival and excellent local control for patients with PC. The low rate of local recurrence among men with relapse suggests that these patients were micro metastasised at time of treatment, which calls for improved methods to detect disseminated disease.
Asunto(s)
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Neoplasias de la Próstata / Braquiterapia Tipo de estudio: Observational_studies / Risk_factors_studies Límite: Aged / Humans / Male Idioma: En Revista: Acta Oncol Asunto de la revista: NEOPLASIAS Año: 2021 Tipo del documento: Article País de afiliación: Suecia

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Neoplasias de la Próstata / Braquiterapia Tipo de estudio: Observational_studies / Risk_factors_studies Límite: Aged / Humans / Male Idioma: En Revista: Acta Oncol Asunto de la revista: NEOPLASIAS Año: 2021 Tipo del documento: Article País de afiliación: Suecia